Type 1 diabetes mellitus is a metabolic disorder characterised by hyperglycaemia due to absolute insulin deficiency.
Patients most often present with a few days or weeks of polyuria, polydipsia, weight loss, and weakness.
Some patients may present with diabetic ketoacidosis.
Intensive glycaemic control has been shown to decrease the incidence of microvascular and macrovascular complications.
Microvascular complications include retinopathy, nephropathy, and neuropathy.
Macrovascular complications include coronary artery, cerebrovascular, and peripheral vascular disease.
Type 1 diabetes mellitus is a metabolic disorder characterised by hyperglycaemia due to absolute insulin deficiency. The condition develops due to destruction of pancreatic beta cells, mostly by immune-mediated mechanisms. In some patients there may be no evidence of autoimmune destruction of pancreatic beta cells; this is called idiopathic type 1 diabetes.
History and exam
Rajesh K. Garg, MD
Professor of Medicine
University of Miami, Miller School of Medicine
RKG is an author of a number of references cited in this topic.
Varsha Vimalananda, MD, MPH
Section of Endocrinology, Diabetes, Nutrition and Weight Management
Boston University School of Medicine
Center for Healthcare Organization and Implementation Research
Edith Nourse Rogers Memorial VA Medical Center
VV declares that she has no competing interests.
Zachary Bloomgarden, MD
Diabetes and Bone Disease
Mount Sinai School of Medicine
ZB declares that he has no competing interests.
Alicia Jenkins, MB, BS, MD, FRACP, FRCP
Department of Medicine
University of Melbourne
Harold Hamm Oklahoma Diabetes Center
University of Oklahoma Health Sciences Center
AJ has been a (non-salaried) co-investigator on multi-center clinical trials supported by Novo, Eli Lilly, Sanofi-Aventis, and Medtronic. She does not hold any stocks or shares in these companies. She has received a speaker's honorarium from Novo.
Use of this content is subject to our disclaimer